Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06891755 · ClinicalTrials.gov registry record · NA

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

A NA study of COPD and Emphysema, sponsored by Apreo Health.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
19
Study locations

NCT06891755 is a NA study of COPD and Emphysema that is actively recruiting participants, run by Apreo Health. The registered enrollment target is 250 participants, below the 2,415-participant average among 85 other COPD trials with a reported enrollment target (90% lower). The trial reports 19 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06891755, a NA study of COPD and Emphysema, is actively recruiting participants, sponsored by Apreo Health.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
19
Study locations

Study Summary

The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The main questions it aims to answer are: Is it safe? Does it work?

Conditions Studied

COPD Emphysema

Interventions

  • DEVICE Apreo BREATHE Airway Scaffold
  • OTHER Optimal Medical Management (OMM)

Study Locations (19)

Pennsylvania

  • Clinical Research Associates of Central Pennsylvania - DuBois
  • Temple University - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Florida

  • Mayo Clinic - Jacksonville
  • Orlando Health - Orlando

Illinois

  • University of Chicago - Chicago
  • OSF St Francis Medical Center - Peoria

Ohio

  • Cleveland Clinic Foundation - Cleveland
  • The Ohio State University - Columbus

Other

  • University Medical Center Groningen - Groningen
  • Royal Brompton Hospital - London

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Banner Health - Gilbert

California

  • University of California at Davis - Sacramento

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-07-15
Est. Completion 2029-12-31
Phase NA

Sponsor

Apreo Health

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06891755

The ClinicalTrials.gov registry entry for NCT06891755 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,415-participant average among 85 other COPD trials with a reported enrollment target (90% lower). The listed sponsor is Apreo Health, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COPD appearing as the primary indexed condition, and to 2 interventions - of which Apreo BREATHE Airway Scaffold is the first listed.

NCT06891755 reports 19 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06891755 about?

NCT06891755 is a clinical study titled "Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3". The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATH...

What is the current status of trial NCT06891755?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2025-07-15. Estimated completion is 2029-12-31.

What conditions does trial NCT06891755 study?

This clinical trial studies the following conditions: COPD, Emphysema.

What interventions are being tested in trial NCT06891755?

The interventions under investigation include: Apreo BREATHE Airway Scaffold (DEVICE), Optimal Medical Management (OMM) (OTHER).

Who is sponsoring clinical trial NCT06891755?

This trial is sponsored by Apreo Health, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06891755 being conducted?

This trial has 19 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COPD

All registered trials for this condition

Emphysema

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.